Sortera Bio woos antibody discovery specialist as Chair

Dr Llewellyn is CEO and co-founder of DJS Antibodies. He helped the company develop a groundbreaking antibody discovery platform and took it from inception through to its successful acquisition by AbbVie, the sixth largest biomedical companies by revenue in the US.

Sortera Bio is making a name for itself in its own right – based on IP developed at the MRC Laboratory of Molecular Biology. The company is focused on accelerating the discovery of biologics via its proprietary Deep Screening platform and is dedicated to delivering transformative solutions in biologics discovery to meet the needs of patients worldwide.

Dr Llewellyn brings exceptional leadership experience and industry expertise to Sortera at a crucial moment as the business prepares for its next funding round and accelerates the commercialisation of its proposition.

His experience in steering DJS Antibodies positions him well to provide strategic guidance to Sortera’s management team as they scale operations and expand partnerships.

Beyond executive experience, the new man has a strong background in evolutionary immunology, antibody discovery and development. He holds a PhD in Clinical Medicine from the University of Oxford, where he studied as a Rhodes Scholar.

His commitment to positive impact extends beyond his biotechnology as co-founder of Beyond Equality, an organisation dedicated to promoting positive masculinity and gender equality.

Ben Porebski, CEO/CTO at Sortera Bio, said: “I’m excited by the addition of David to the team. His recent experiences in taking DJS, a platform antibody company, from inception to success are highly relevant for Sortera as we progress through our next phase of growth. I look forward to learning from David as we leverage Deep Screening for developing next generation biologics.”

Dr Llewellyn added: “Sortera’s technology is the biggest leap in antibody discovery since phage display with the potential to revolutionise the space. I have little doubt that Deep Screening will be central to the discovery of the next generation of life saving biologics and it’s an absolute pleasure to work with the team to make that a reality.”